197 related articles for article (PubMed ID: 10980901)
1. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.
Ennezat PV; Berlowitz M; Sonnenblick EH; Le Jemtel TH
Curr Cardiol Rep; 2000 May; 2(3):258-62. PubMed ID: 10980901
[TBL] [Abstract][Full Text] [Related]
2. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).
Pitt B; Chang P; Grossman W; Dunlay M; Timmermans PB
Am J Cardiol; 1996 Nov; 78(10):1129-31. PubMed ID: 8914876
[TBL] [Abstract][Full Text] [Related]
5. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Granger CB; McMurray JJ; Yusuf S; Held P; Michelson EL; Olofsson B; Ostergren J; Pfeffer MA; Swedberg K;
Lancet; 2003 Sep; 362(9386):772-6. PubMed ID: 13678870
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
8. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
9. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
10. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
Rapezzi C
Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
[No Abstract] [Full Text] [Related]
12. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
13. Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress.
Ellis GR; Nightingale AK; Blackman DJ; Anderson RA; Mumford C; Timmins G; Lang D; Jackson SK; Penney MD; Lewis MJ; Frenneaux MP; Morris-Thurgood J
Eur J Heart Fail; 2002 Mar; 4(2):193-9. PubMed ID: 11959049
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.
Bhakta S; Dunlap ME
Cleve Clin J Med; 2004 Aug; 71(8):665-73. PubMed ID: 15449762
[TBL] [Abstract][Full Text] [Related]
15. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Sigurdsson A; Swedberg K
Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
[TBL] [Abstract][Full Text] [Related]
16. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
[TBL] [Abstract][Full Text] [Related]
20. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
